| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
|
15,541 |
14,580 |
$681K |
| 99214 |
|
7,168 |
6,770 |
$500K |
| 99203 |
|
5,900 |
5,723 |
$340K |
| 87635 |
|
6,288 |
5,909 |
$293K |
| 87502 |
|
2,180 |
2,098 |
$191K |
| 87651 |
|
4,303 |
4,101 |
$138K |
| 99204 |
|
1,062 |
1,008 |
$100K |
| 99212 |
|
1,729 |
1,658 |
$28K |
| 99211 |
|
1,811 |
1,688 |
$27K |
| 71046 |
|
2,431 |
2,295 |
$27K |
| 81025 |
|
1,717 |
1,641 |
$11K |
| 96374 |
|
391 |
364 |
$10K |
| 74177 |
|
75 |
67 |
$9K |
| 99202 |
|
318 |
305 |
$8K |
| 87880 |
|
2,098 |
2,013 |
$8K |
| 80048 |
|
1,120 |
1,078 |
$7K |
| 85025 |
|
1,033 |
983 |
$7K |
| 99201 |
|
215 |
204 |
$6K |
| 80053 |
|
593 |
562 |
$5K |
| 81001 |
|
1,856 |
1,776 |
$5K |
| 87804 |
|
695 |
327 |
$4K |
| 93000 |
|
462 |
426 |
$4K |
| 99000 |
|
377 |
369 |
$4K |
| 85027 |
|
710 |
681 |
$4K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
40 |
40 |
$2K |
| 84484 |
|
209 |
193 |
$2K |
| 36415 |
|
769 |
744 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
153 |
144 |
$1K |
| 87081 |
|
369 |
342 |
$1K |
| 83690 |
|
190 |
182 |
$1K |
| 81003 |
|
866 |
831 |
$1K |
| 87634 |
|
14 |
14 |
$857.52 |
| 87491 |
|
27 |
27 |
$825.05 |
| 87591 |
|
27 |
27 |
$825.05 |
| 94640 |
|
76 |
68 |
$706.03 |
| 87210 |
|
117 |
115 |
$623.32 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
344 |
310 |
$513.15 |
| 96375 |
|
26 |
25 |
$428.48 |
| 96361 |
|
48 |
41 |
$407.84 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
56 |
51 |
$31.49 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
27 |
24 |
$8.64 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
905 |
817 |
$0.00 |
| 96360 |
|
12 |
12 |
$0.00 |